{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T06:02:59Z","timestamp":1770703379271,"version":"3.49.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s40249-016-0196-8","type":"journal-article","created":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T09:30:25Z","timestamp":1475573425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Alternatives to currently used antimalarial drugs: in search of a magic bullet"],"prefix":"10.1186","volume":"5","author":[{"given":"Akshaya Srikanth","family":"Bhagavathula","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asim Ahmed","family":"Elnour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulla","family":"Shehab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,4]]},"reference":[{"key":"196_CR1","unstructured":"World Health Organization. 10 facts on malaria. Available at: http:\/\/www.who.int\/features\/factfiles\/malaria\/en.html . Accessed 9 Feb. 2016."},{"issue":"9","key":"196_CR2","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2165\/00003495-200262090-00003","volume":"62","author":"F Nosten","year":"2002","unstructured":"Nosten F, Brasseur P. Combination therapy for malaria. Drugs. 2002;62(9):1315\u201329.","journal-title":"Drugs"},{"key":"196_CR3","unstructured":"Medicines for Malaria venture. Available information: http:\/\/www.mmv.org\/about-us\/our-history.html . Accessed 9 Feb. 2016."},{"key":"196_CR4","unstructured":"World Health Organization: Malaria fact sheet. Available at http:\/\/www.who.int\/mediacentre\/factsheets\/fs094\/en.html . Accessed 28 Jan. 2016"},{"key":"196_CR5","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.bmcl.2013.03.067","volume":"23","author":"MA Biamonte","year":"2013","unstructured":"Biamonte MA, Wanner J, Le Roch KG. Recent advances in malaria drug discovery. Bioorg Med Chem Lett. 2013;23:2829\u201343.","journal-title":"Bioorg Med Chem Lett"},{"key":"196_CR6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Taming T, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367.","journal-title":"N Engl J Med"},{"key":"196_CR7","unstructured":"Clinical trials.gov. Available at https:\/\/clinicaltrials.gov\/ct2\/results?term=Phase+3+malaria+vaccine&Search=Search.html . Accessed 10 June 2015"},{"key":"196_CR8","doi-asserted-by":"crossref","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;11:e1001685.","DOI":"10.1371\/journal.pmed.1001685"},{"key":"196_CR9","doi-asserted-by":"crossref","first-page":"e1000406","DOI":"10.1371\/journal.pmed.1000406","volume":"8","author":"PL Alonso","year":"2011","unstructured":"Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, et al. A research agenda to underpin malaria eradication. PLoS Med. 2011;8:e1000406.","journal-title":"PLoS Med"},{"issue":"5","key":"196_CR10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda RM, Fairhurst C, Amaratunga P, Lim S, Suon S, et al. Spreading of artemisinin resistance in Plasmodium falciparum malaria. N Eng J Med. 2014;371(5):411\u201323.","journal-title":"N Eng J Med"},{"issue":"3","key":"196_CR11","doi-asserted-by":"crossref","first-page":"e1000830","DOI":"10.1371\/journal.ppat.1000830","volume":"6","author":"S Vinayak","year":"2010","unstructured":"Vinayak S, Alam MT, Mixaon-Hayden T, McCollum AM, Sem R, Shah NK, et al. Origin and evolution of sulfadoxine resistant Plasmodium falciparum. PLoS Pathog. 2010;6(3):e1000830.","journal-title":"PLoS Pathog"},{"issue":"6","key":"196_CR12","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1128\/AAC.01228-06","volume":"51","author":"AM McCollum","year":"2007","unstructured":"McCollum AM, Mueller K, Villegas L, Udhyakumar V, Escalante AA. Common origin and fixation of Plasmodium falciparum and dhps mutations associated with sulphadoxine-pyramethamine resistance in a low-transmission area in South America. Antimicrob Agents Chemother. 2007;51(6):2085\u201391.","journal-title":"Antimicrob Agents Chemother"},{"key":"196_CR13","unstructured":"Clinical trials.gov. Available at https:\/\/clinicaltrials.gov\/ct2\/results?term=novel+antimalarial+drug&Search=Search.html Accessed 22 June 2015."},{"key":"196_CR14","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"issue":"5996","key":"196_CR15","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1126\/science.1193225","volume":"329","author":"M Rottmann","year":"2010","unstructured":"Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, et al. Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010;329(5996):1175\u201380.","journal-title":"Science"},{"key":"196_CR16","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1128\/AAC.03393-14","volume":"58","author":"FJ Leong","year":"2014","unstructured":"Leong FJ, Li R, Jain JP, Lefevre G, Magnusson B, Diagana TT, et al. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial spiroindolone KAE609 (cipargamin), to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers. Antimicrob Agents Chemother. 2014;58:6209\u201314.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"196_CR17","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1128\/AAC.00340-15","volume":"59","author":"DS Stein","year":"2015","unstructured":"Stein DS, Jain JP, Kangas M, Lefevre G, Machineni S, Griffin P, et al. Open-label, parallel-group study in healthy volunteers to determine in the safety.in healthy volunteers to determine the drug-drug interactions potential between KAE609 (Cipargamin) and piperaquine. Antimicrob Agents Chemother. 2015;59(6):3493\u2013500.","journal-title":"Antimicrob Agents Chemother"},{"key":"196_CR18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa1315860","volume":"371","author":"JW Nicholus","year":"2014","unstructured":"Nicholus JW, Sasithon P, Phyo AP, Reuangweerayut R, Nosten F, Podjanee J, et al. Spiroindolone KAE609 for falciparum and vivax malaria. N Eng J Med. 2014;371:403\u201310.","journal-title":"N Eng J Med"},{"issue":"9","key":"196_CR19","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1128\/AAC.02838-15","volume":"60","author":"M Chavchich","year":"2016","unstructured":"Chavchich M, Van Breda K, Rowcliffe K, Diagana TT, Edstein MD. The spiroindolone KAE609 does not induce dormant ring stage in Plasmodium falciparum parasites. Antimicrob Agents Chemother. 2016;60(9):5167\u201374.","journal-title":"Antimicrob Agents Chemother"},{"key":"196_CR20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14451","volume":"522","author":"B Baragana","year":"2015","unstructured":"Baragana B, Hallyburton I, Lee MC, Norcross NR, Raffaella G, Otto TD, et al. A novel multiple-stage antimalarial agent than inhibits protein synthesis. Nature. 2015;522:315\u201320.","journal-title":"Nature"},{"key":"196_CR21","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1038\/ncomms6521","volume":"5","author":"AB Vaidya","year":"2014","unstructured":"Vaidya AB, Morrisey JM, Zhang Z, Das S, Daly TM, Otto TD, et al. Pyrazoleamide compounds are potent antimalarials that target Na\u2009+\u2009homeostasis in intraerythrocytic Plasmodium falciparum. Nature Commun. 2014;5:5521.","journal-title":"Nature Commun"},{"key":"196_CR22","unstructured":"Novartis Pharmaceuticals. Efficacy, safety, tolerability and pharmacokinetics of KAF156 in adult patients with acute, uncomplicated Plasmodium falciparum or vivax malaria mono-infection. In:ClinicalTrials.gov. Bethesda (MD). [Cited 2015 Nov 19] Available from: http:\/\/clinicaltrial.gov\/show\/NCT01753323 ."},{"issue":"269","key":"196_CR23","doi-asserted-by":"crossref","first-page":"296ra111","DOI":"10.1126\/scitranslmed.aaa6645","volume":"7","author":"MA Phillips","year":"2015","unstructured":"Phillips MA, Lotharius J, Marsh K, White J, Dayan A, White KL, et al. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci Translat Med. 2015;7(269):296ra111.","journal-title":"Sci Translat Med"},{"issue":"2","key":"196_CR24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/bdrb.21054","volume":"98","author":"DA Beckman","year":"2013","unstructured":"Beckman DA, Youreneff M, Butt MT. Neurotoxicity assessment of artemether in juvenile rats. Birth Defects Res B Dev Reprod Toxicol. 2013;98(2):183\u201399.","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"7","key":"196_CR25","doi-asserted-by":"crossref","first-page":"e41123","DOI":"10.1371\/journal.pone.0041123","volume":"7","author":"M Luntamo","year":"2012","unstructured":"Luntamo M, Rantala AM, Meshnick SR, Cheung YB, Kulmala T, Maleta K, et al. The effect of monthly sulfadoxine-pyrimethamine, alone or with azithromycin, on PCR-diagnosed malaria at delivery: a randomized controlled trial. PLoS One. 2012;7(7):e41123.","journal-title":"PLoS One"},{"key":"196_CR26","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.4269\/ajtmh.2010.10-0228","volume":"83","author":"R Tansley","year":"2010","unstructured":"Tansley R, Lotharius J, Priestley A, Bull F, Duparc S, Mohrle J. A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of single enantiomer (+)-mefloquine compared with racemic mefloquine in healthy persons. Am J Trop Med Hyg. 2010;83:1195\u2013201.","journal-title":"Am J Trop Med Hyg"},{"key":"196_CR27","doi-asserted-by":"crossref","first-page":"E5455","DOI":"10.1073\/pnas.1414221111","volume":"111","author":"MB Jimenez-Diaz","year":"2014","unstructured":"Jimenez-Diaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, et al. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci U S A. 2014;111:E5455\u201362.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7479","key":"196_CR28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature12782","volume":"504","author":"CW McNamara","year":"2013","unstructured":"McNamara CW, Lee MC, Lim CS, Lim SH, Roland K, Nagle A, et al. \u201cTargeting Plasmodium PI(4) K to eliminate malaria. Nature. 2013;504(7479):248\u201353.","journal-title":"Nature"},{"issue":"7","key":"196_CR29","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1021\/jm3001373","volume":"55","author":"Y Younis","year":"2012","unstructured":"Younis Y, Douelle F, Feng TS, Gonzales Cabrera D, Le Manach C, Nichinda AT, et al. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem. 2012;55(7):3479\u201387.","journal-title":"J Med Chem"},{"key":"196_CR30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Watkowski C, Amaratunga J, Beghain AC, Langois N, Khim S, et al. A molecular-marker of artesmisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50\u20135.","journal-title":"Nature"},{"issue":"5","key":"196_CR31","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1128\/AAC.04067-14","volume":"59","author":"G Henriques","year":"2015","unstructured":"Henriques G, van Schalkwyk DA, Burrow R, Warhurst DC, Thompson E, Baker DA, et al. The Mu subunit of Plasmodium falciparum clathrin-associated adaptor protein 2 modulates in vitro parasite response to artesmisinin and quinine. Antimicrob Agents Chemother. 2015;59(5):2540\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"196_CR32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1179\/2047773214Y.0000000158","volume":"108","author":"J Li","year":"2014","unstructured":"Li J, Chen J, Xie D, Monte-Nguba SM, Eyi JU, Matesa RA, et al. High prevalence of pfmdr1 N86Y and Y184F mutations in Plasmodium falciparum isolates from Bioko Island, Equatorial Guinea. Pathog Glob Health. 2014;108:339\u201343.","journal-title":"Pathog Glob Health"},{"key":"196_CR33","doi-asserted-by":"crossref","first-page":"8614","DOI":"10.1038\/ncomms9614","volume":"6","author":"B St Laurent","year":"2015","unstructured":"St Laurent B, Miller B, Burton TA, Amaratunga C, Men S, Sovannaroth S, et al. Artemisinin-resistant Plasmodium falciparum clinical isolates can infect diverse mosquitoes vectors of Southeast Asia and Africa. Nat Commun. 2015;6:8614.","journal-title":"Nat Commun"},{"issue":"5","key":"196_CR34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/cid\/cis475","volume":"55","author":"N Valecha","year":"2012","unstructured":"Valecha N, Krudsood S, Tangpukdee N, Mohanty S, Sharma SK, Tyagi PK, et al. Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial. Clin Infect Dis. 2012;55(5):663\u201371. Patil CY, Katara SS, Baig MS, Doifode SM. Fixed dose combination of arterolane and piperaquine: A newer prospect in antimalarial therapy. Ann Med Health Sci Res 2014;4(4):466\u2013471.","journal-title":"Clin Infect Dis"},{"issue":"7002","key":"196_CR35","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nature02779","volume":"430","author":"JL Vennerstrom","year":"2004","unstructured":"Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, Chollet J, et al. Indentification of an antimalarial synthetic trioxolane drug development candidate. Nature. 2004;430(7002):900\u20134.","journal-title":"Nature"},{"key":"196_CR36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1473-3099(15)00320-5","volume":"16","author":"AP Phyo","year":"2016","unstructured":"Phyo AP, Jittamala P, Nosten FH, Pukrittayakamee S, Imwong M, White NJ, et al. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: a open-lable phase 2 trial. Lancet Infect Dis. 2016;16:61\u20139.","journal-title":"Lancet Infect Dis"},{"key":"196_CR37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/bdrb.20092","volume":"77","author":"S Ritter","year":"2006","unstructured":"Ritter S, Laffan SB, Clark RL. Artesunate-induced depletion of embryonic erythroblasts precedes embryolethality and teratogenicity in vivo. Birth Defects Res B Dev Reprod Toxicol. 2006;77:413\u201329.","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"196_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00547-2","author":"KA Moore","year":"2016","unstructured":"Moore KA, Simpson JA, Paw MK, Pimanpanarak MP, Wiladphaingern J, Rijken MJ, et al. Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. Lancet Infect Dis. 2016. doi: 10.1016\/S1473-3099(15)00547-2 .","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"196_CR39","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nrd4573","volume":"14","author":"TNC Wells","year":"2015","unstructured":"Wells TNC, van Huijsduijnen RH, Van Voorhis WC. Malaria medicines: a glass half full? Nat Rev Drug Discov. 2015;14(6):424\u201342.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"196_CR40","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkl563","volume":"59","author":"L Vivas","year":"2007","unstructured":"Vivas L, Rattray L, Stewart LB, Robinson BL, Fugmann B, Haynes RK, et al. Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo. J Antimicrob Chemother. 2007;59(4):658\u201365.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"196_CR41","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1128\/AAC.01585-07","volume":"52","author":"J Nagelschmitz","year":"2008","unstructured":"Nagelschmitz J, Voith B, Wensing G, Roemer A, Fugmann B, Haynes RK, et al. First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone. Antimicrob Agents Chemother. 2008;52(9):3085\u201391.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"196_CR42","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000252658","volume":"84","author":"B Medhi","year":"2009","unstructured":"Medhi B, Patyar S, Rao RS, Bayrav DSP, Praksh A. Pharmacokinetic and toxicological profile of artemisinin compounds: an update. Pharmacol. 2009;84(6):323\u201332.","journal-title":"Pharmacol"},{"issue":"1","key":"196_CR43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4269\/ajtmh.2012.11-0192","volume":"86","author":"G Carrasquilla","year":"2012","unstructured":"Carrasquilla G, Baron C, Monsell EM, Cousin M, Walter V, Lefevre G, et al. Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg. 2012;86(1):75\u201383.","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"196_CR44","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.1128\/AAC.02462-14","volume":"58","author":"CA Lanteri","year":"2014","unstructured":"Lanteri CA, Chaorattanakawee S, Lon C, Saunders DL, Rutvisuttinunt W, Yingyuen K, et al. Ex Vivo activity of endoperoxide antimalarials, including artemisone and arteolane, against multidrug-resistant Plasmodium falciparum isolates from Cambodia. Antimicrob Agents Chemother. 2014;58(10):5831\u201340.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7549","key":"196_CR45","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nature14387","volume":"520","author":"A Mbengye","year":"2015","unstructured":"Mbengye A, Bhattacharjee S, Pandhakar T, Liu H, Estiu G, Stahelin RV, et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature. 2015;520(7549):628\u201330.","journal-title":"Nature"},{"key":"196_CR46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1475-2875-10-53","volume":"10","author":"G Mombo-Ngoma","year":"2011","unstructured":"Mombo-Ngoma G, Sapan C, Dal-Bianco MP, Missinou MA, Matsiegui PB, Ospina Salazar CL, et al. Phase I randomized dose-ascending placebo-controlled trials of ferroquine\u2014a candidate anti-malarial drug-in adults with asymptomatic Plasmodium falciparum infection. Malar J. 2011;10:53.","journal-title":"Malar J"},{"issue":"9","key":"196_CR47","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1128\/AAC.01375-10","volume":"55","author":"K Marfurt","year":"2011","unstructured":"Marfurt K, Chalfein F, Prayoga P, Wabiser F, Kenangalem E, Piera KA, et al. Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P.vivax. Antimicrob Agents Chemother. 2011;55(9):4461\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"196_CR48","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1128\/AAC.00283-12","volume":"56","author":"K Marfurt","year":"2012","unstructured":"Marfurt K, Chalfein F, Prayoga P, Wabiser F, Wirjanata G, Sebayang B, et al. Comparative ex vivo activity of novel endoperoxides in multidrug-resistant Plasmodium falciparum and P.vivax. Antimicrob Agents Chemother. 2012;56(10):5258\u201363.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"196_CR49","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1473-3099(15)00079-1","volume":"15","author":"J Held","year":"2015","unstructured":"Held J, Supan C, Salazar CL, Tinto H, Bonkian LN, Nahum A. Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomized, double-blind, dose-ranging, non-inferiority study. Lancet Infect Dis. 2015;15(12):1409\u201319.","journal-title":"Lancet Infect Dis"},{"key":"196_CR50","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/10915810490471352","volume":"23","author":"S Ramanathan-Girish","year":"2004","unstructured":"Ramanathan-Girish S, Catz P, Creek MR, Wu B, Thomas D, et al. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgous macaques. Int J Toxicol. 2004;23:179\u201389.","journal-title":"Int J Toxicol"},{"issue":"1","key":"196_CR51","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1371\/journal.pctr.0020006","volume":"2","author":"F Mzayek","year":"2007","unstructured":"Mzayek F, Deng H, Mather JF, Wasilevich EC, Liu H, Hadi CM, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials. 2007;2(1):e6.","journal-title":"PLoS Clin Trials"},{"issue":"2","key":"196_CR52","first-page":"10","volume":"13","author":"SR Marcsisin","year":"2014","unstructured":"Marcsisin SR, Sousa JC, Reichard GA, Caridha D, Zeng Q, Careaganarja J, et al. Tafenoquine and NPC-1161B requires CYP2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compound. Malaria J. 2014;13(2):10\u20131186.","journal-title":"Malaria J"},{"issue":"9922","key":"196_CR53","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(13)62568-4","volume":"383","author":"A Llanos-Cuentas","year":"2014","unstructured":"Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383(9922):1049\u201358.","journal-title":"Lancet"},{"key":"196_CR54","unstructured":"GSK and MMV announce start of Phase III programme of tafenoquine for Plasmodium vivax malaria. Available at: http:\/\/us.gsk.com\/en-us\/media\/press-release\/2014\/gsk-and-mmv-announce-start-of-phase-iii-programme-of-tafenoquine-for-plasmodium-vivax-malaria.html . Accessed: 11 Jul 2015."},{"key":"196_CR55","first-page":"953","volume":"28","author":"P Ehrlich","year":"1891","unstructured":"Ehrlich P, Guttmann P. Ueber die Wirkung des Methylenblaubei Malaria. BerlKlinWochenschr. 1891;28:953\u20136.","journal-title":"BerlKlinWochenschr"},{"issue":"5","key":"196_CR56","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0006-2952(95)02258-9","volume":"51","author":"H Atamna","year":"1996","unstructured":"Atamna H, Krugliak M, Shalmiev G, Deharo E, Pescarmona G, Ginsburg H. Mode of antimalarial effect of methylene blue and some of its analogues on Plasmodium falciparum in culture and their inhibition of P. vinckeipetteri and P. yoeliinigeriensis in vivo. Biochem Pharmacol. 1996;51(5):693\u2013700.","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"196_CR57","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1365-3156.2010.02526.x","volume":"15","author":"M Bountogo","year":"2010","unstructured":"Bountogo M, Zoungrana A, Coulibaly B, Klose C, Mansmann U, Mockenhaupt FP, et al. Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso. Trop Med Int Health. 2010;15(6):713\u20137.","journal-title":"Trop Med Int Health"},{"issue":"10","key":"196_CR58","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00228-004-0818-0","volume":"60","author":"J Rengelshausen","year":"2004","unstructured":"Rengelshausen J, Burhenne J, Frohlich M, Tayrouz Y, Singh SK, Riedel KD, et al. Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol. 2004;60(10):709\u201315.","journal-title":"Eur J Clin Pharmacol"},{"key":"196_CR59","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/nyas.12766","volume":"1342","author":"S Takala-Harrison","year":"2015","unstructured":"Takala-Harrison S, Laufer MK. Antimalarial drug resistance in Africa: key lessons for the future. Ann N Y Acad Sci. 2015;1342:62\u20137.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"196_CR60","doi-asserted-by":"crossref","first-page":"e1630","DOI":"10.1371\/journal.pone.0001630","volume":"3","author":"A Zoungrana","year":"2008","unstructured":"Zoungrana A, Coulibaly B, Sie A, Walter-Sack I, Mockenhaupt FP, Kouyate B, et al. Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. PLoS One. 2008;3(2):e1630.","journal-title":"PLoS One"},{"issue":"5","key":"196_CR61","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/infdis\/jiu540","volume":"211","author":"B Coulibaly","year":"2015","unstructured":"Coulibaly B, Pritsch M, Bountogo M, Meissner PE, Nebie E, Klose C, et al. Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomised controlled trial in Burkina Faso. J Infect Dis. 2015;211(5):689\u201397.","journal-title":"J Infect Dis"},{"key":"196_CR62","first-page":"1","volume":"1","author":"S Oyakhirome","year":"2011","unstructured":"Oyakhirome S, Issifou S, Pongratz P, BorondiF RM, Kun JF, et al. Molecular basis of fosmidomycin\u2019s action on the human malaria parasite Plasmodium falciparum. Sci Res. 2011;1:1\u20138.","journal-title":"Sci Res"},{"issue":"2","key":"196_CR63","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1128\/AAC.47.2.735-738.2003","volume":"47","author":"B Lee","year":"2003","unstructured":"Lee B, Ruangweerayut R, Wiesner J, Missinou MA, Schindler A, Baranek T, et al. Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrob Agents Chemother. 2003;47(2):735\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"196_CR64","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/1475-2875-7-225","volume":"7","author":"R Ruangweerayut","year":"2008","unstructured":"Ruangweerayut R, Looareesuwan S, Hutchinson D, Chauemung A, Banmairuroi V, Na-Bangchang K. Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin clindamycin in patients with acute uncomplicated falciparum malaria. Malar J. 2008;7:225.","journal-title":"Malar J"},{"issue":"9","key":"196_CR65","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1128\/AAC.49.9.3749-3754.2005","volume":"49","author":"S Borrmann","year":"2005","unstructured":"Borrmann S, Adegnika AA, Moussavou F, Oyakhirome S, Esser G, Matseiegui P, et al. Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2005;49(9):3749\u201354.","journal-title":"Antimicrob Agents Chemother"},{"key":"196_CR66","first-page":"1","volume":"17","author":"S Abbas","year":"2014","unstructured":"Abbas S, Jain V, Bhartam PV. Origin of the specificity of inhibitor P218 towards wild-type and mutant PfDHFR: a molecular dynamics analysis. J Biomol Struct Dyn. 2014;17:1\u201316.","journal-title":"J Biomol Struct Dyn"},{"issue":"15","key":"196_CR67","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1021\/jm200592f","volume":"54","author":"JM Corteron","year":"2011","unstructured":"Corteron JM, Marco M, Esquivias J, Deng X, White KL, White J, et al. Structure-guided lead optimization of triazolopyrimidine-ring substituents identified potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitor with clinical candidate potential. J Med Chem. 2011;54(15):5540\u201361.","journal-title":"J Med Chem"},{"issue":"2","key":"196_CR68","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00709-014-0697-x","volume":"252","author":"S Kumar","year":"2015","unstructured":"Kumar S, Kumari R, Pandey R. New insight-guided approaches to detect, cure, prevent and eliminate malaria. Protoplasma. 2015;252(2):717\u201353.","journal-title":"Protoplasma"},{"issue":"9","key":"196_CR69","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1128\/AAC.02727-13","volume":"58","author":"KL Kuhen","year":"2014","unstructured":"Kuhen KL, Chatterjee AK, Rottmann M, Gagaring K, Borboa R, Buenviaje J, et al. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment and prevention of disease transmission. Antimicrob Agents Chemother. 2014;58(9):5060\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"196_CR70","doi-asserted-by":"publisher","DOI":"10.1128\/ACC.01183-15","author":"GP Miley","year":"2015","unstructured":"Miley GP, Pou S, Winter R, Nilsen A, Li Y, Kelly JX, et al. ELQ-300 prodrug for enhanced development and single dose cure of malaria. Antimicrob Agents Chemother. 2015. doi: 10.1128\/ACC.01183-15 .","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"196_CR71","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/jac\/dkt486","volume":"69","author":"T Antoine","year":"2014","unstructured":"Antoine T, Fisher N, Amewu R, O\u2019Neill PM, Ward SA, Biagini GA. Rapid kill of malaria parasites by artemisin and semi-synthetic endoperoxides involves ROS-dependent polorization of the membrane potential. J Antimicrob Chemother. 2014;69(4):1005\u201316.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"196_CR72","doi-asserted-by":"crossref","first-page":"e26916","DOI":"10.1371\/journal.pone.0026916","volume":"6","author":"MB Cassera","year":"2011","unstructured":"Cassera MB, Hazleton KZ, Merino EF, Obaldia 3rd N, Ho MC, Murkin AS, et al. Plasmodium falciparum parasites are killed by a transition state analogue of purine nucleoside phosphorylase in primate animal model. PLoS One.2011;6(11):e26916.","journal-title":"PLoS One"},{"issue":"1\u20132","key":"196_CR73","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.chroma.2006.01.040","volume":"1110","author":"AK Dutta","year":"2006","unstructured":"Dutta AK, Avery BA, Wyandt CM. Development and validation of a stability-indicating reversed-phase high performance method for NPC1161C, a novel 8-aminoquinoline anti-malarial drug. J Chromatogr A. 2006;1110(1\u20132):35\u201345.","journal-title":"J Chromatogr A"},{"issue":"7","key":"196_CR74","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1128\/AAC.00030-12","volume":"56","author":"SD Sumanadasa","year":"2012","unstructured":"Sumanadasa SD, Goodman CD, Lucke AJ, Skinner-Adams T, Sahama I, Haque A, et al. Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. Antimicrob Agents Chemother. 2012;56(7):3849\u201356.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"196_CR75","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ja.2012.123","volume":"66","author":"B Somanadhan","year":"2013","unstructured":"Somanadhan B, Kotturi SR, Yan Leong C, Glover RP, Huang Y, Flotow H, et al. Isolation and synthesis of falcitidin, a novel myxobacterial-derived acylretrapeptide with activity against the malaria target falcipain-2. J Antibiot (Tokyo). 2013;66(5):259\u201364.","journal-title":"J Antibiot (Tokyo)"},{"issue":"18","key":"196_CR76","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.4155\/fmc.12.177","volume":"4","author":"JM Bueno","year":"2012","unstructured":"Bueno JM, Herreros E, Angulo-Barturer I, Ferrer S, Fiandor JM, Gamo FJ, et al. Exploration of 4(1H)-pyridones as a novel family of potent antimalarial inhibitors of the plasmodial cytochromebc1. Future Med Chem. 2012;4(18):2311\u201323.","journal-title":"Future Med Chem"},{"issue":"7","key":"196_CR77","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1128\/AAC.02721-13","volume":"58","author":"K Trenholme","year":"2014","unstructured":"Trenholme K, Marek L, Duffy S, Pradel G, Fisher G, Hansen FK, et al. Lysine acetylation in sexual stage malarial parasites is a target for antimalarial small molecules. Antimicrob Agents Chemother. 2014;58(7):3666\u201378.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"196_CR78","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1021\/ml4004952","volume":"5","author":"K Jaudzems","year":"2014","unstructured":"Jaudzems K, Tars K, Maurops G, Ivdra N, Otikovs M, Leitans J, et al. Plasmepsin inhibitory activity and structure-guided optimization of a potent hydroxyethylamine-based antimalarial hit. ACS Med Chem Lett. 2014;5(4):373\u20137.","journal-title":"ACS Med Chem Lett"},{"key":"196_CR79","unstructured":"Working together to fight malaria with new medicines: Development of an active Toll-like receptor (TLR) 9 antagonist, Access to medicines: Eisai. Available at http:\/\/www.eisai.com\/company\/atm\/activities\/04.html Accessed on 12 Feb 2016"},{"key":"196_CR80","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1128\/AAC.01714-10","volume":"55","author":"RH Barker Jr","year":"2011","unstructured":"Barker Jr RH, Urgaonkar S, Mazitschek R, Celatka C, Skerlj R, Cortese JF, et al. Aminoindoles, a novel scaffold with potent activity against Plasmodium falciparum. Antimicrob Agents Chemother. 2011;55:2612\u201322.","journal-title":"Antimicrob Agents Chemother"},{"key":"196_CR81","doi-asserted-by":"crossref","first-page":"33054","DOI":"10.1074\/jbc.M110.162081","volume":"285","author":"ML Booker","year":"2010","unstructured":"Booker ML, Bastos CM, Kramer ML, Barker Jr RH, Skerlj R, Sidhu AB, et al. Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with anti-malarial activity in the mouse model. J Biol Chem. 2010;285:33054\u201364.","journal-title":"J Biol Chem"},{"key":"196_CR82","doi-asserted-by":"crossref","unstructured":"O\u2019Neill PM, Amewu RK, Nixon GL, Bousejra ElGarah F, Mungthin M, Chadwick J, et al. Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins. Angew Chem Int Ed Engl. 2010;49:5693\u201397.","DOI":"10.1002\/anie.201001026"}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-016-0196-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T00:18:02Z","timestamp":1498349882000},"score":1,"resource":{"primary":{"URL":"http:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-016-0196-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,4]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["196"],"URL":"https:\/\/doi.org\/10.1186\/s40249-016-0196-8","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,4]]},"article-number":"103"}}